Navigation Links
Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinson's Disease
Date:4/15/2008

Effort utilizes Phreesia's automated patient check-in system to enable

better management of medication wear-off

NEW YORK, April 15 /PRNewswire/ -- Phreesia, Inc., the Patient Check-In Company, has announced that it will integrate a new screening tool developed by researchers at Duke University Medical Center into its electronic patient intake process, thereby potentially enhancing the ability of doctors to identify and manage the debilitating symptoms of Parkinson's disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/NYW106LOGO )

Affecting about one million people in the United States, Parkinson's disease is a degenerative disorder that impairs nerve cells causing patients to experience tremors, slowness of movement, muscle rigidity, and difficulty with balance. Drug therapy is highly effective, but within 2 years of initiating treatment up to 50% of patients can experience a decrease in drug efficacy, a phenomenon that is referred to as "wearing-off".

"Recognition of wearing-off and under treatment in Parkinson's disease patients is a major problem", said Mark Stacy, MD, Director of the Movement Disorders Center at Duke University's School of Medicine. Research has shown that nearly half of all patients that report wearing-off are not identified in a routine clinical exam. To help address this inconsistency, Phreesia will automate the "Wearing-Off Questionnaire-9" (WOQ-9), a highly sensitive screening tool specifically designed by researchers at Duke to identify these symptoms in the clinical setting.

Frequently, paper screening tools are cumbersome to implement clinically. As part of Phreesia's electronic patient intake system patients with Parkinson's disease will answer questions from the WOQ-9 and the results will be made available to their physician prior to starting the clinical exam. By enabling physicians nationwide to automate the WOQ-9 in their waiting room a higher identification rate of wearing-off is anticipated, ideally resulting in subsequent treatment and potentially better patient outcomes.

Physicians who use Phreesia will have the option to seamlessly integrate the WOQ-9 into their existing intake process and evaluate responses at both the patient and practice level. "This is Phreesia at its best -- leveraging evidence-based clinical assessment tools to improve patient care", said Chaim Indig, CEO of Phreesia. The implementation of the WOQ-9 is one of many clinical initiatives that Phreesia is developing for physicians who use their electronic patient check-in system.

About Phreesia:

Phreesia is the patient check-in company. Phreesia automates patient check-in and delivers fully interactive content direct-to-patients, designed to interface with physicians' existing and future technology. Replacing the outdated patient clipboard with a free wireless touch-screen and swipe-card enabled PhreesiaPad significantly improves the patient experience. Phreesia is committed to the ideals of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Phreesia is backed by premier venture capital firms and draws on the expertise of a leading Medical Advisory Board. http://www.phreesia.com


'/>"/>
SOURCE Phreesia, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
4. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
5. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
6. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
7. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
8. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
9. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
10. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
11. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... Jones Industrial Average edged 0.36% higher, to finish at 19,191.93; ... were broad based as six out of nine sectors ended ... on the following Services equities: Myriad Genetics Inc. (NASDAQ: ... INC Research Holdings Inc. (NASDAQ: INCR ), and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Yisrayl Hawkins, ... delves into how this current generation fits into Bible Prophecy. Yisrayl says this generation, ... facts pointing to this conclusion, showing how the details line up exactly with Bible ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, Inc., ... $6.0 million in an initial round of funding. The round was led by ... caregivers can receive far better care through the application of the best technologies ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, ... connected applications, was named the best Sales Team of 2016 as part of ... made today by the Software & Information Industry Association (SIIA), the principal trade ...
Breaking Medicine News(10 mins):